Clinical Trial Update: Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab with or without docetaxel in previously treated metastatic pancreatic cancer; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Pancreatic Cancer | Phase 2 | Status: TERMINATED | Results posted: 2021-03-05